ACAD EBITDA Growth
Acadia Pharmaceuticals Inc · EBITDA Growth
ACAD EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-8.89%period ending
ACAD TTM EBITDA YoY % (-13.96% → -8.89%)
Year-over-year change
High-resolution chart · PNG
ACAD ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -8.8942% | |
| 2.2948% | |
| 25.6989% | |
| -10.3195% | |
| 122.81% | |
| 385.3907% | |
| 363.5234% | |
| 217.1146% | |
| 155.6915% | |
| 117.7646% | |
| 78.4862% | |
| 40.3783% | |
| 48.9701% | |
| 31.7146% | |
| -28.506% | |
| -13.2183% | |
| 22.5427% | |
| 19.1737% | |
| 41.9998% | |
| 30.9857% | |
| -11.686% | |
| -6.0619% | |
| -16.357% | |
| -7.3027% | |
| 13.9075% | |
| 11.344% | |
| 0.27% | |
| -3.3968% | |
| -7.8556% | |
| -8.903% | |
| 15.2989% | |
| 17.3976% | |
| 17.7993% | |
| 17.6015% | |
| -6.4959% | |
| -24.7744% | |
| -48.0378% | |
| -77.9032% | |
| -65.2712% | |
| -62.4414% | |
| -54.7372% | |
| -50.3047% | |
| -76.2629% | |
| -91.7957% | |
| -112.8639% | |
| -131.1685% | |
| -143.4074% | |
| -133.0648% | |
| -155.4489% | |
| -141.1231% | |
| -83.939% | |
| -70.7418% | |
| -11.5045% | |
| 10.2529% | |
| 7.9319% | |
| -259.9917% | |
| -269.3257% | |
| -250.4429% | |
| -243.7205% | |
| 155.0199% | |
| 149.2908% | |
| 144.195% | |
| 135.3983% | |
| 56.5011% | |
| 53.9142% | |
| 44.854% | |
| 33.1212% | |
| 28.2108% | |
| 21.4685% | |
| 5.6102% | |
| -7.8384% | |
| -22.7379% | |
| -41.0299% | |
| -29.364% | |
| -26.9453% | |
| -25.7752% | |
| -12.8196% | |
| -31.6039% | |
| -39.2974% | |
| -44.6299% | |
| -84.0635% | |
| -62.0705% | |
| -40.3076% | |
| 15.0931% | |
| 14.7515% | |
| 5.4077% | |
| -13.9615% |